• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer invests $130 million in two Irish manufacturing sites

Pfizer invests $130 million in two Irish manufacturing sites

July 12, 2013
CenterWatch Staff

Pfizer is investing $130 million in two of its Irish manufacturing sites, $100 million in the Grange Castle site in Dublin and $30 million in the Ringaskiddy site in Cork. 

The investments, which are supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland, will enable the sites to expand their capacity and begin producing more advanced, complex therapies for difficult to cure diseases. 

“We are seeing the benefits of the investments we’ve been making in our innovative core, as evidenced by recent key launches of medicines for stroke prevention, rheumatoid arthritis and cancer,” said Dr. Paul Duffy, vice president, Pfizer. “There is opportunity for Pfizer’s Irish sites to attract the development of new medicines, while also continuing to manufacture existing medicines.”

The $30 million investment in Ringaskiddy is to develop specialist new capability to manufacture Pfizer’s newest medicines in cancer. This requires flexible development facilities capable of managing a wide range of processes and technology. The introduction of flow processing and innovative technologies requires not just an investment in new equipment but also an increase and deepening of R&D skills, particularly in the area of real-time analytical technologies, flow processing, new technology and scale-up. This investment ensures the Ringaskiddy site will be in a position to be considered for ongoing development work on new products, for both commercial launch and clinical trials.

The $100 million investment in Grange Castle is to create additional manufacturing capacity by expanding the unit that produces protein drug substance using mammalian cell culture biotechnology. This unit makes drug substance for Pfizer’s biologic rheumatoid arthritis treatment. This will release capacity to allow new mammalian biotechnology drug substances from Pfizer’s development pipeline to be manufactured at the site. Preparation is underway to allow construction over the next year, with a peak of 250 construction jobs. The facility will be operational in 2015, when the first process validation batches will be made.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing